Roivant Sciences Is Determined to Help Patients Suffering From Alzheimer’s
If at first you don’t succeed, you keep trying. That is the position taken by revolutionary biotech company Roivant Sciences. Medical research in the field of Alzheimer’s Disease has come a long way in the past few decades, but we have yet to find a cure. The medications that have been developed in the field of Alzheimer’s Disease research have been successful in slowing the development of the disease, but these medications do not stop the development. There have also been advancements in the diagnosis of the disease, which has allowed for earlier detection and treatment.
Alzheimer’s disease first came to the forefront of research in the early 1990s after former president Ronald Reagan disclosed his diagnosis of the disease. Since then, many companies and organizations, including The Fischer Center for Alzheimer’s Research Foundation, have made discoveries and paved new paths in the course of medical research. The Fischer Center has been a national leader in medical research, as well as education, resources, and support for patients and their loved ones.
The true cost of Alzheimer’s Disease
Providing support for caregivers has become vital as they are an integral part of the care system. Without family caregivers, a more significant burden would be placed on nursing facilities, and the need for specialized centers designed for dementia patients would be required. The cost of care would skyrocket when it is already tremendous. Healthcare costs in the United States are already significantly higher than in other Western Countries due to the burden placed on the healthcare system.
Many understand the actual cost of Alzheimer’s, which is significant and widespread. Patients get to the point of requiring around-the-clock nursing care as they gradually lose the ability to care for themselves in even the most basic ways. They will forget to feed themselves, go to the bathroom, speak, and eventually move. During the early stages, patients are often aware that they are slowly losing their memories and ability to recognize people, places, and things that were once quite common. This awareness can lead to depression, frustration, and outburst of aggression or even violence.
The cost is also seen in the toll it takes on the family. While losing a loved one is always intensely sad, slowly watching a loved one lose the person they once were is traumatizing. Further, trying to care for a loved one with Alzheimer’s is exhausting and can quickly take over every aspect of their lives. The mental and emotional impact is so significant that the Alzheimer’s Association created a network of support groups for people caring for a loved one.
Roivant Sciences’ commitment to a cure
In 2017, Roivant Sciences announced the disappointing outcomes of their biopharma research. Vivek Ramaswamy, CEO of Roivant, explained that they were working on a receptor antagonist intepirdine, which was believed to have the potential as a serious treatment for the development of Alzheimer’s. However, it failed in almost every outcome being tested. While many research companies may focus on any silver lining they can glean from failed research, Ramaswamy took a different approach. He fully acknowledged their failure. In an interview with Fierce Biotech, Ramaswamy stated, “I think failure is an option to learn; we should be open about it, learn from it, but communicate honestly what has happened while not at the same time overreacting to it.”
Ramaswamy went on to say that Rovient Sciences is not ready to throw in the towel. They went to work on what they can learn from the failed research to continue to work towards developing a cure that will be available to help people all over the world facing a diagnosis of Alzheimer’s Disease. Roivant Sciences has taken on the mission of Alzheimer’s research and is not deterred by early failures.